Skip to main content
logo
Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
16.64
-0.41 (-2.40%)
Jul 31, 2026, 12:15 PM EDT - Market open

Kailera Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025
Period Ending
Mar '26 Dec '25
Cash & Equivalents
111.83160.27
Short-Term Investments
407.35385.79
Cash & Short-Term Investments
519.17546.06
Cash Growth
--
Other Current Assets
11.1411.48
Total Current Assets
530.32557.54
Net Property, Plant & Equipment
12.0212.42
Long-Term Investments
62.75106.67
Other Long-Term Assets
19.6715.67
Total Assets
624.76692.29

Liabilities

Fiscal Year
TTMFY 2025
Period Ending
Mar '26 Dec '25
Accounts Payable
7.17.53
Accrued Expenses
46.7137.84
Current Portion of Leases
1.031.04
Total Current Liabilities
54.8446.41
Long-Term Leases
9.449.71
Other Long-Term Liabilities
0.20.27
Total Long-Term Liabilities
9.649.98
Total Liabilities
64.4856.39

Shareholders' Equity

Fiscal Year
TTMFY 2025
Period Ending
Mar '26 Dec '25
Additional Paid-in Capital
15.9811.98
Accumulated Other Comprehensive Income
-0.530.23
Retained Earnings
-447.53-368.67
Total Common Shareholders' Equity
-432.09-356.46
Minority Interest
992.36992.36
Shareholders' Equity
560.28635.91
Total Liabilities & Equity
624.76692.29

Additional Metrics

Fiscal Year
TTMFY 2025
Period Ending
Mar '26 Dec '25
Total Debt
10.4710.75
Net Cash (Debt)
508.7535.3
Net Cash Growth
--
Net Cash Per Share
16983.413409573.25
Book Value
-432.09-356.46
Book Value Per Share
-14425.50-2270433.00
Tangible Book Value
-432.09-356.46
Tangible Book Value Per Share
-14425.50-2270433.00
SEC Filings: 10-K · 10-Q